Sharemaestro company-news research for Immuron Ltd ADR (IMRN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

Latest IMRN news and sentiment

Immuron Ltd ADR

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research RSS feed
30-day score55Neutral is 50
Early balanced news score 30/100 evidence confidence 100% direct company focus 15 current stories across 5 publishers
Latest weekly closeUSD 1.80week of 4 Sep 2026
Main news subjectEarnings81/100 share of current news
News data statusPartial14 duplicate stories removed

Current company news

Early balanced news score

15 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone66/100 Published 30-day score55/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Immuron Signs Exclusive US Distribution Deal for Digestive-Health Product PROIBS MT Newswires · 04 Sep 2026 17:51

What supports the score

Direct evidence

15 current stories are mapped specifically to IMRN.

Source breadth

The score uses 5 publishers rather than depending on one outlet.

What limits the score

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.443.

Confidence

Confidence is 30/100, below the threshold for a firm score.

55/100
News scoreEarly balanced news score
30/100
Confidencethin evidence
100%/100
Company news15 company stories
87/100
Story agreement13/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
13 Aug: 2 stories18 Aug: 1 stories19 Aug: 1 stories28 Aug: 7 stories04 Sep: 4 stories 13 Aug: tone 50, 2 stories18 Aug: tone 50, 1 stories19 Aug: tone 59, 1 stories28 Aug: tone 63, 7 stories04 Sep: tone 52, 4 stories 95505
08 Aug23 Aug06 Sep
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence9
0.443 after freshness weighting
Source breadth100
5 independent publishers
Company relevance100
share tied directly to this company
Freshness35
recency-weighted evidence
Agreement87
how closely stories agree
Publisher mix79
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks12 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Mar 2026: close 0.783, indexed 100.020 Mar 2026: close 0.703, indexed 89.827 Mar 2026: close 0.80496, indexed 102.803 Apr 2026: close 0.801, indexed 102.310 Apr 2026: close 0.793, indexed 101.317 Apr 2026: close 0.9578, indexed 122.324 Apr 2026: close 0.8935, indexed 114.101 May 2026: close 0.792, indexed 101.108 May 2026: close 0.8049, indexed 102.815 May 2026: close 1.005, indexed 128.422 May 2026: close 1.0, indexed 127.729 May 2026: close 1.45, indexed 185.205 Jun 2026: close 1.25, indexed 159.612 Jun 2026: close 1.19, indexed 152.019 Jun 2026: close 1.06, indexed 135.426 Jun 2026: close 1.1, indexed 140.503 Jul 2026: close 1.1, indexed 140.510 Jul 2026: close 1.23, indexed 157.117 Jul 2026: close 1.21, indexed 154.524 Jul 2026: close 1.11, indexed 141.831 Jul 2026: close 1.09, indexed 139.207 Aug 2026: close 1.031, indexed 131.714 Aug 2026: close 1.1, indexed 140.521 Aug 2026: close 1.12, indexed 143.028 Aug 2026: close 1.15, indexed 146.904 Sep 2026: close 1.8, indexed 229.9 19 Jun 2026: news score 51, close 1.06, 1 stories5126 Jun 2026: news score 50, close 1.1, 4 stories03 Jul 2026: news score 50, close 1.1, 6 stories5010 Jul 2026: news score 50, close 1.23, 7 stories17 Jul 2026: news score 58, close 1.21, 16 stories5824 Jul 2026: news score 53, close 1.11, 18 stories31 Jul 2026: news score 51, close 1.09, 27 stories5107 Aug 2026: news score 53, close 1.031, 27 stories14 Aug 2026: news score 51, close 1.1, 26 stories5121 Aug 2026: news score 52, close 1.12, 16 stories28 Aug 2026: news score 58, close 1.15, 12 stories5804 Sep 2026: news score 54, close 1.8, 15 stories54 Price index 246.7 159.8 73.0 News score 100 50 0
13 Mar09 Jun04 Sep
Weekly close, indexedSentiment score
26-week price+129.9%latest close 1.80
News score change+3first to latest comparable week
One-week response+2.7%Price confirming higher
Fair-value position-35.3%Below fair value
WeekNews scoreCloseWeekly move
04 Sep 202654USD 1.8+56.5%
28 Aug 202658USD 1.15+2.7%
21 Aug 202652USD 1.12+1.8%
14 Aug 202651USD 1.1+6.7%
07 Aug 202653USD 1.031-5.4%
31 Jul 202651USD 1.09-1.8%
24 Jul 202653USD 1.11-8.3%
17 Jul 202658USD 1.21-1.6%
Provisional evidence

News subjects

What is shaping the score

Earnings
Earnings679 stories · 60%
Market update533 stories · 20%
Balance sheet452 stories · 13%
Deals and strategy501 stories · 7%

Source mix

Where the evidence comes from

79/100 independence
Stock Titan474 stories · 27%
Kalkine792 stories · 13%
Kalkine Media642 stories · 13%
GlobeNewswire502 stories · 13%
Quiver Quantitative711 stories · 7%
Stocktwits571 stories · 7%
MT Newswires501 stories · 7%

Recurring subjects

Subjects appearing most often

Current evidence
Earnings7Life Sciences6Finance3Ratings1Earnings News1

Earlier readings

How the score has changed

22 comparable readings · 79 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+351 to 54 · Broadly stable
Observed range50–6050 is the neutral baseline
Evidence depth15stories at latest stored reading · +14
Confidence25/100Provisional · -4
19 Jun50 neutral06 Sep 15:17
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
06 Sep 15:1754+025/100 (-3)15 (0)Provisional
04 Sep 23:5954-428/100 (-12)15 (+3)Provisional
28 Aug 23:5958+640/100 (+10)12 (-6)Measured
19 Aug 23:5952+130/100 (+13)18 (-2)Provisional
18 Aug 23:5951-117/100 (-3)20 (-8)Provisional
13 Aug 23:5952-220/100 (-9)28 (+1)Provisional
05 Aug 23:5954+229/100 (-4)27 (0)Provisional
28 Jul 23:5952+033/100 (-2)27 (0)Provisional

Source headlines

The news behind the score

Showing 1-15 of 15

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#1—Not directional
MT NewswiresDirect company coverageScored from headline

Immuron Signs Exclusive US Distribution Deal for Digestive-Health Product PROIBS

Published
04 Sep 2026 17:51
News subject
Deals and strategy
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 0.2d old
Duplicates
1 consolidated
#3—Not directional
InvestorsHubDirect company coverageScored from headline

Immuron Plans U.S. PROIBS Launch Under Exclusive Distribution Agreement

Published
04 Sep 2026 13:53
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 0.4d old
Duplicates
1 consolidated
#4—Not directional
GlobeNewswireDirect company coverageScored from headline

Immuron to launch PROIBS® in the United States

Published
04 Sep 2026 10:00
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 0.5d old
Duplicates
1 consolidated
#542Tone
Stock TitanDirect company coverageScored from headline

Immuron (NASDAQ: IMRN) ends FY26 with A$9.0m cash but stays in loss

Published
28 Aug 2026 12:45
News subject
Balance sheet
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 44/100
30-day weight
14.9% of the score · 7.4d old
Duplicates
1 consolidated
#6—Not directional
seekingalpha.comDirect company coverageStored article

Immuron reports FY results

* Immuron press release [https://seekingalpha.com/pr/20633267-immuron-reports-fy26-preliminary-results] (IMRN [https://seekingalpha.com/symbol/IMRN]): FY record sales of A$7.7 million, growth of 6% on pcp. * Net loss of A$3.8M, improvement of A$1.4M. MORE ON IMMURON * Immuron Limited (IMRN) Presents at 95th Emerging Growth Conference - Slideshow [https://seekingalpha.com/article/4938454-immuron-limited-imrn-presents-at-95th-emerging-growth-conference-slideshow] * Seeking Alpha’s Quant Rating on Immuron [https://seekingalpha.com/symbol/IMRN/ratings/quant-ratings] * Historical earnings data for

EarningsEarnings NewsRatings
Published
28 Aug 2026 10:12
News subject
Earnings
Why this score
Operating growth
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 7.5d old
Duplicates
1 consolidated
#8—Not directional
Stock TitanDirect company coverageScored from headline

Immuron's cash rose A$6.2M to A$9M; its C. diff drug is ready for Phase 2

Published
28 Aug 2026 10:00
News subject
Balance sheet
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 7.5d old
Duplicates
1 consolidated
#9—Not directional
GlobeNewswireDirect company coverageScored from headline

Immuron Reports FY26 Preliminary Results

Published
28 Aug 2026 10:00
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 7.5d old
Duplicates
1 consolidated
#1081Tone
KalkineDirect company coverageStored article

Immuron Limited Reports 5.9% Revenue Rise and Reduced Full-Year Loss in Appendix 4E

Immuron Limited (ASX:IMC) announced a 5.9% increase in revenue to $7,713,601 for the year ended June 30, 2026, primarily driven by Travelan® sales in Australia and North America. The company also significantly reduced its net loss after tax by 26.4% to $3,838,699. Immuron's cash and cash equivalents substantially increased to $9,017,814, and audited financial statements are expected by September 30, 2026.

EarningsFinanceLife Sciences
Published
28 Aug 2026 09:15
News subject
Earnings
Why this score
Loss narrowed, Operating growth
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
High · 67/100
30-day weight
28.8% of the score · 7.6d old
Duplicates
1 consolidated
#1165Tone
Kalkine MediaDirect company coverageStored article

Immuron Reports 6% Rise in FY26 Global Sales to $7.7 Million with Improved Net Loss

Immuron (ASX:IMC) announced its preliminary financial results for fiscal year 2026, reporting a 6% increase in global sales revenue to $7.7 million. The company also saw an improved net loss of $3.8 million, a $1.4 million reduction from the previous year. Immuron achieved key operational milestones, including FDA approval for IMM-529 and completing a large-scale Travelan trial, while maintaining strong cash reserves to fund future operations.

EarningsLife Sciences
Published
28 Aug 2026 09:15
News subject
Earnings
Why this score
Operating growth, Improving financial comparison, Fda Approval
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 52/100
30-day weight
21.8% of the score · 7.6d old
Duplicates
1 consolidated
#1259Tone
Stock TitanDirect company coverageStored article

Immuron (IMRN) lifts FY26 sales as it shifts to partner-funded drug development

Immuron Ltd (IMRN) reported a 6% increase in global sales revenue to A$7.7 million for FY2026, driven by strong performance in Australia and the U.S. The company is strategically repositioning itself as a commercially focused biopharmaceutical business, relying on over-the-counter products like Travelan and ProIBS, while seeking partners to fund the development and commercialization of its clinical assets IMM-124E and IMM-529. This shift aims to reduce R&D expenditure and cash burn, leveraging upfront fees, milestones, and royalties from licensing agreements.

EarningsLife Sciences
Published
19 Aug 2026 10:11
News subject
Earnings
Why this score
Cash generation improved, Strategic partnership
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 37/100
30-day weight
4.6% of the score · 16.5d old
Duplicates
1 consolidated
#13—Not directional
KalkineDirect company coverageStored article

Immuron CEO Steven Lydeamore to Present at Emerging Growth Conference

Immuron Limited's CEO, Steven Lydeamore, is scheduled to present at the Emerging Growth Conference on August 19, 2026, from 4:25pm to 4:35pm U.S. Eastern Time. The Australian biopharmaceutical company, dual-listed on ASX (IMC) and NASDAQ (IMRN), specializes in developing orally delivered targeted polyclonal antibodies for infectious diseases. Immuron's product portfolio includes Travelan® for Travelers' Diarrhea, IMM-529 for Clostridioides difficile infection, and ProIBS® for IBS symptoms.

EarningsFinanceLife Sciences
Published
18 Aug 2026 23:40
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 17.0d old
Duplicates
1 consolidated
#14—Not directional
Stock TitanDirect company coverageStored article

Immuron Limited (NASDAQ: IMRN) highlights antibody platform and CEO talk at Emerging Growth Conference

Immuron Limited announced that CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on August 19, 2026. The company highlighted its orally delivered targeted polyclonal antibody platform, featuring its lead product Travelan® for travelers' diarrhea, pipeline asset IMM-529 for C. difficile infection, and the distribution of ProIBS® for IBS symptoms. The presentation will cover Immuron's proprietary technology based on hyper-immune bovine colostrum-derived immunoglobulins and its applications.

EarningsLife Sciences
Published
13 Aug 2026 09:42
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 22.5d old
Duplicates
1 consolidated
#15—Not directional
Kalkine MediaDirect company coverageStored article

Immuron CEO Steven Lydeamore to Deliver Virtual Presentation at Emerging Growth Conference on August 19, 2026

Immuron Limited (ASX:IMC) announced that its CEO, Steven Lydeamore, will deliver a virtual presentation at the Emerging Growth Conference on August 19, 2026, from 4:25 pm to 4:35 pm U.S. Eastern Time. The company, an Australian biopharmaceutical firm, specializes in orally delivered targeted polyclonal antibodies for infectious diseases, with its flagship product Travelan AE targeting travelers' diarrhea. Immuron is also developing IMM-529 for Clostridioides difficile infection.

EarningsFinanceLife Sciences
Published
13 Aug 2026 09:15
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 22.6d old
Duplicates
2 consolidated

Earlier company news

IMRN news archive

Showing 1-30 of 32 stored headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Aug 13 2026
KalkineArchivedNeutral tone

Immuron CEO Steven Lydeamore to Present at Emerging Growth Conference on 19 August 2026

Immuron Limited CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on August 19, 2026, from 4:25pm to 4:35pm U.S. Eastern Time. The biopharmaceutical company, listed on both ASX and NASDAQ, focuses on orally delivered targeted polyclonal antibodies for infectious diseases. Immuron's product portfolio includes Travelan® for traveler's diarrhea and a pipeline candidate, IMM-529, for recurrent Clostridioides difficile infection.

EarningsFinanceLife Sciences
Published
13 Aug 2026 07:40
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 30 2026
TradingKeyArchivedLegacy headline · tone unscoredLegacy source lookup

IMRN|Immuron Ltd|Price:1.070|Chg%:-0.025

Published
30 Jul 2026 18:11
Catalyst
Legacy snapshot
Coverage
Direct company
Duplicates
1 consolidated
Jul 28 2026
TradingKeyArchivedNeutral tone

Immuron Ltd (IMRN) Cash Flow

This article provides an in-depth look at Immuron Ltd (IMRN) cash flow statements, including operating, investing, and financing cash flows, both quarterly and annually. It highlights the company's negative operating cash flow and free cash flow in the latest fiscal period, alongside explanations of what each cash flow metric signifies for investors.

EarningsFinanceLife Sciences
Published
28 Jul 2026 03:12
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 27 2026
TradingKeyArchivedNegative tone

IMRN|Immuron Ltd|Price:1.110|Chg%:-0.060

This TradingKey analysis of Immuron Ltd (IMRN) focuses on its stock performance and proprietary stock score. The article details how TradingKey generates its comprehensive stock score based on 34 indicators across six dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment. It notes that a stock score for Immuron Ltd is currently unavailable due to insufficient data but explains the methodology behind each scoring dimension.

EarningsFinancial MarketsLife Sciences
Published
27 Jul 2026 14:16
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 27 2026
KalkineArchivedNeutral tone

Immuron CEO Steven Lydeamore Presents at TechKnow Invest Roadshow as Company Advances Polyclonal Antibody Pipeline

Immuron Limited's CEO, Steven Lydeamore, presented at the TechKnow Invest Roadshow, highlighting the company's progress in oral polyclonal antibody therapies. The presentation covered their commercial product Travelan® for travelers' diarrhea, the investigational drug IMM-529 for recurrent Clostridioides difficile infection, and the distributed product ProIBS® for irritable bowel syndrome. Immuron emphasizes its platform technology using hyper-immune bovine colostrum to develop targeted treatments for infectious diseases and gastrointestinal conditions.

FinanceLife Sciences
Published
27 Jul 2026 13:39
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 27 2026
Stock TitanArchivedPositive tone

Immuron (NASDAQ: IMRN) outlines FY26 growth, cash runway and CDI IND plans

Immuron Limited shared an investor update detailing FY26 sales, cash position, and plans for its clinical assets. The company reported global sales revenue of A$7.7 million for FY26, a 6% increase from the previous year, and maintains a strong cash balance of A$10.0 million as of December 31, 2025. Immuron is strategically pursuing partnerships for its key clinical assets, IMM-124E and IMM-529, to reduce R&D expenses and accelerate monetization, with IMM-529 having an FDA-approved IND for Clostridioides difficile infection.

EarningsFinanceLife Sciences
Published
27 Jul 2026 13:16
Catalyst
Earnings
Coverage
Direct company
Duplicates
2 consolidated
Jul 27 2026
TradingKeyArchivedNeutral tone

Immuron Ltd (IMRN) Institutional Confidence

This article focuses on the institutional confidence in Immuron Ltd (IMRN), detailing the shareholding and activity of various financial institutions. Key institutions like Morgan Stanley & Co. LLC and Citadel Advisors LLC significantly increased their holdings, while others like XTX Markets LLC and Rhumbline Advisers Ltd. Partnership reduced theirs. The data also shows the company's current stock price, market cap, and recent performance.

FinanceFinancial Markets
Published
27 Jul 2026 09:13
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 27 2026
TradingKeyArchivedPositive tone

Immuron Ltd (IMRN) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Immuron Ltd (IMRN), indicating a "Buy" rating based on one analyst's assessment. The target price for IMRN is set at USD 5.00, representing a significant upside. The report includes current market data and a peer comparison, but notes that specific financial forecasting data like EPS, Revenue, EBIT, and Net Profit have not yet been disclosed by the company.

EarningsFinancial MarketsLife Sciences
Published
27 Jul 2026 00:16
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 27 2026
TradingKeyArchivedNeutral tone

Immuron Ltd (IMRN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Immuron Ltd (IMRN), focusing on its volatility, financial risk, and investment risk based on various metrics. It details the company's market performance, including daily returns, drawdowns, Sharpe Ratios, and different measures of volatility and liquidity. The data points aim to inform potential investors about the inherent risks associated with IMRN stock.

Financial MarketsLife Sciences
Published
27 Jul 2026 00:13
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 26 2026
TradingKeyArchivedNeutral tone

Immuron Ltd (IMRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Immuron Ltd (IMRN), focusing on various indicators and moving averages. It presents a summary of "Sell," "Neutral," and "Buy" signals from nine common technical indicators and six moving averages. The analysis concludes with a "Neutral" signal based on overall technical indicators and answers frequently asked questions about technical ratings and moving averages.

FinanceFinancial MarketsLife Sciences
Published
26 Jul 2026 23:13
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 26 2026
TradingKeyArchivedNeutral tone

Immuron Ltd (IMRN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Immuron Ltd (IMRN) for Fiscal Year 2023, showcasing its business segments and regional contributions. Travelan accounts for the vast majority of revenue at 96.68%, with Protectyn making up the remaining 3.32%. Geographically, Australia generates 64.31% of revenue, followed by the United States at 35.62%, and Canada at a minor 0.07%.

EarningsLife Sciences
Published
26 Jul 2026 10:09
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 26 2026
TradingKeyArchivedNeutral tone

Immuron Ltd (IMRN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for Immuron Ltd (IMRN). It states that the company has distributed a total of $0.00 in dividends over the past five years and shows "No Data" for specific dividend dates. The article includes current stock pricing and market capitalization information.

EarningsFinanceFinancial MarketsLife Sciences
Published
26 Jul 2026 10:09
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 25 2026
TradingKeyArchivedNeutral tone

Immuron Ltd (IMRN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Immuron Ltd (IMRN), listing major individual and institutional holders as of recent reporting periods. It highlights the proportion of shares held by entities such as Morgan Stanley, Citadel Advisors, and XTX Markets, alongside a breakdown by shareholder type. The report also provides quarterly changes in institutional shareholding and shareholder activity.

FinanceFinancial MarketsLife Sciences
Published
25 Jul 2026 12:39
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 23 2026
Stock TitanArchivedNegative tone

Immuron’s Travelan uses oral antibodies to reduce diarrhea risk

Immuron (NASDAQ: IMRN; ASX: IMC) announced that CEO Steven Lydeamore would present at a Kalkine Media Webinar on July 20, 2026, to discuss the company's developments in orally delivered targeted polyclonal antibodies for infectious diseases. Their flagship product, Travelan (IMM‑124E), is designed to prevent travelers' diarrhea. The presentation also covered IMM‑529 for recurrent Clostridioides difficile infection and ProIBS for irritable bowel syndrome, highlighting the company's platform technology using hyper-immune bovine colostrum to produce antibodies that remain active in the GI tract.

EarningsFinancial MarketsLife Sciences
Published
23 Jul 2026 17:42
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 22 2026
KalkineArchivedNeutral tone

Immuron CEO Steven Lydeamore to Present at TechKnow Invest Roadshow in Melbourne

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced that CEO Steven Lydeamore will present at the TechKnow Invest Roadshow in Melbourne on July 27, 2026. He will discuss the company's immunotherapy products, including its key commercial product Travelan® for travelers' diarrhea and its investigational drug, IMM-529, for recurrent Clostridioides difficile infection (CDI). Immuron is also expanding its gastrointestinal health portfolio with a distribution agreement for ProIBS® in Australia and New Zealand.

EarningsFinancial MarketsLife Sciences
Published
22 Jul 2026 00:40
Catalyst
Earnings
Coverage
Direct company
Duplicates
2 consolidated
Jul 21 2026
Stock TitanArchivedNeutral tone

Immuron Limited (NASDAQ: IMRN) highlights antibody platform at TechKnow Invest

Immuron Limited announced that its CEO, Steven Lydeamore, will present at the TechKnow Invest Roadshow to highlight the company's orally delivered targeted polyclonal antibody platform. The presentation will cover its products like Travelan for travelers' diarrhea and IMM-529 for recurrent C. difficile infection, and ProIBS for irritable bowel syndrome. The company detailed preclinical data for IMM-529 and market information for its distributed products.

Life Sciences
Published
21 Jul 2026 10:41
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 20 2026
Kalkine MediaArchivedNeutral tone

Immuron CEO Steven Lydeamore to Unveil Strategic Vision at Kalkine Media Webinar on July 20, 2026

Immuron Limited (ASX: IMC; NASDAQ: IMRN) CEO Steven Lydeamore will present the company's strategic vision at a Kalkine Media Webinar on July 20, 2026, at 12:30 PM AEST. He is expected to discuss the company's clinical pipeline and commercial products, including its flagship traveler's diarrhea treatment, Travelan®, and other investigational therapies for infectious diseases. The presentation offers insights into Immuron's future direction in its biopharmaceutical focus.

Life Sciences
Published
20 Jul 2026 22:11
Catalyst
Market update
Coverage
Direct company
Duplicates
3 consolidated
Jul 20 2026
Stock TitanArchivedPositive tone

Immuron Limited (NASDAQ: IMRN) grows FY26 revenue to A$7.7m

Immuron Limited reported FY26 global sales revenue of A$7.7 million, a 6% increase from the previous year, driven by strong growth in Australia and the US. The biopharmaceutical company is pursuing a strategic shift towards partnering its clinical assets, IMM-124E and IMM-529, to reduce R&D costs and cash burn, while focusing on over-the-counter commercialization of its existing products like Travelan and ProIBS. This strategy aims to accelerate monetization and improve profitability, supported by a healthy cash balance of A$10.0 million as of December 31, 2025.

EarningsFinanceLife Sciences
Published
20 Jul 2026 13:11
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 20 2026
KalkineArchivedNeutral tone

Immuron CEO to Present Company Strategy at Kalkine Media Webinar

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced that CEO Steven Lydeamore will virtually present the company's strategy at the Kalkine Media Webinar on July 20, 2026, at 12:30 PM AEST. The presentation will cover its clinical pipeline and commercial products, including Travelan® for travellers' diarrhea and investigational therapies like IMM-529 for C. difficile infection and ProIBS® for IBS. This event aims to communicate the company's strategic direction to investors and stakeholders, highlighting its dual listing on ASX and NASDAQ, and its focus on developing orally delivered targeted polyclonal antibodies for infectious diseases.

EarningsLife Sciences
Published
20 Jul 2026 10:10
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 16 2026
scanx.tradeArchivedPositive tone

Immuron FY26 sales rise 6% to AUD$7.7 million led by Australia

Immuron Limited reported a 6% increase in global revenue to AUD$7.7 million for FY26, driven by four consecutive quarters of sales growth, primarily stemming from strong performance in Australia. Australian sales rose 10% to AUD$5.8 million, while U.S. sales grew 7% in AUD terms to AUD$1.8 million, and Canadian sales showed a significant second-half recovery. The growth was attributed to strong demand for its immune supplement Travelan®, supported by digital marketing efforts and store expansion.

EarningsLife Sciences
Published
16 Jul 2026 11:42
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 16 2026
markets.businessinsider.comArchivedNeutral tone

Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year

Immuron Limited reported continued sales growth for Travelan® in FY26, with global sales reaching AUD$7.7 million, a 6% increase from the prior comparative period. Australia saw a 10% sales increase, driven by marketing and new store growth, while US sales increased by 7% in AUD and 13% in USD due to marketing initiatives. Canadian sales also showed significant quarterly growth, though overall FY26 sales were down, indicating a positive trend in brand awareness.

EarningsLife Sciences
Published
16 Jul 2026 11:42
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 16 2026
Quiver QuantitativeArchivedPositive tone

Immuron Reports FY26 Global Sales Up 6% on Strong Travelan Growth in Australia and the U.S.

Immuron Limited reported a 6% increase in global sales to AUD$7.7 million for FY26, driven by strong growth of its immune supplement Travelan in Australia and the U.S. Australian sales rose by 10% and U.S. sales by 7% (AUD) or 13% (USD), attributed to effective marketing strategies and increased travel. While Canadian sales were down for the full year, they saw significant recovery in the second half, with a 427% increase in Q4.

EarningsEconomy MacroFinanceLife Sciences
Published
16 Jul 2026 11:11
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 16 2026
MoomooArchivedNeutral tone

Immuron 4Q Sales A$2.0M >IMRN

Immuron reported fourth-quarter sales of A$2.0 million. This financial update provides a snapshot of the company's recent sales performance.

EarningsLife Sciences
Published
16 Jul 2026 11:10
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 15 2026
Stock TitanArchivedPositive tone

Immuron's Travelan Sales Grow for Four Straight Quarters

Immuron Limited reported unaudited global Travelan sales of AUD$7.7 million for FY26, a 6% increase from the prior comparative period, marking four consecutive quarters of growth. This growth was fueled by strong performances in Australia and the USA, driven by digital marketing and Amazon store improvements, with Canada also showing significant Q4 recovery despite an overall FY26 decline. The company's stock, IMRN, experienced a 5.04% decline on July 16 following the sales update, contrasting with previous positive market reactions.

EarningsLife SciencesFinance
Published
15 Jul 2026 02:39
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated

Provider matches checked

Provider mentions not used in the score

4 not scored

A news provider linked these stories to IMRN, but the headline and available text are not mainly about Immuron Ltd ADR. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of IMRN sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context